Anti-IL-1β Antibody Neutralization for Insulin Resistance
Solution Overview
Problem
Current treatments for Type 2 diabetes, obesity, hyperglycemia, and insulin resistance, such as IL-1 receptor antagonists, require frequent injections and have limitations in patient compliance and effectiveness due to widespread receptor expression and low measurable IL-1β levels in body fluids.
Innovation Solution
Administering an anti-IL-1β antibody or fragment with high affinity to directly target IL-1β, providing a superior treatment strategy by binding with high specificity and reducing the need for frequent injections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If IL-1 receptor antagonists are administered, then the IL-1 pathway is blocked, but frequent injections are required and patient compliance deteriorates
Solution Approach 1:
The patent changes the therapeutic parameter from blocking the receptor (IL-1Ra) to neutralizing the ligand (IL-1β). This parameter change allows for less frequent administration because the anti-IL-1β antibody directly binds and neutralizes the cytokine itself, maintaining therapeutic effectiveness without requiring frequent injections like receptor antagonists.
Solution Approach 2:
The patent introduces anti-IL-1β antibody as an intermediary that binds to IL-1β with high affinity. This intermediary approach allows the antibody to sequester and neutralize IL-1β in circulation, preventing it from binding to receptors. This mediator strategy improves compliance by reducing injection frequency while maintaining reliable IL-1 pathway blockade.
2Reliability
If IL-1 receptor antagonists are used, then IL-1 signaling is inhibited, but effectiveness is limited due to widespread receptor expression
Solution Approach 1:
The patent extracts the IL-1β cytokine from its biological activity by binding it with high-affinity antibodies. Instead of trying to block the widely distributed receptors, the approach extracts and neutralizes the cytokine itself in circulation, preventing it from activating receptors anywhere in the body. This resolves the limitation of widespread receptor expression by targeting the cytokine source rather than the numerous receptor sites.
3Reliability
If traditional dosing regimens are used, then therapeutic coverage is maintained, but dosing frequency increases and treatment complexity increases
Solution Approach 1:
The patent changes the dosing parameter from frequent administration of receptor antagonists to less frequent administration of anti-IL-1β antibodies. The high affinity and specificity of the antibodies for IL-1β allow for extended therapeutic coverage between doses, simplifying the dosing regimen while maintaining reliable therapeutic coverage.
Data Source
AI summary
Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof.